SCHEMBL4736982

SCHEMBL4736982

COc1ccccc1-c1nc(O)cc(=O)n1Cc1ccccc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.52
GFER P55789 1/20 0.52
CPB1 P15086 1/20 0.47
CASR P41180 1/20 0.46
PTGDR2 Q9Y5Y4 1/20 0.44
KDM4E B2RXH2 1/20 0.44
LMNA P02545 1/20 0.44
HTT P42858 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
MAPT P10636 1/20 0.44
ALOX12 P18054 1/20 0.44
MAPK1 P28482 1/20 0.44
MEN1 O00255 3/20 0.44
RXFP1 Q9HBX9 1/20 0.44
TSHR P16473 1/20 0.44
CXCR2 P25025 1/20 0.44
APLNR P35414 2/20 0.43
P2RX7 Q99572 1/20 0.43
MTNR1A P48039 1/20 0.43
MTNR1B P49286 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4740165 0.82 KDM4E (0.48) KMT2ACASRKDM4ELMNAHTT
SCHEMBL4737515 0.81 CASR (0.45) KMT2ACASRKDM4ELMNAHTT
SCHEMBL5000196 0.81 ALDH1A1 (0.59) KMT2AKDM4ELMNAHTTNPSR1
SCHEMBL4737051 0.79 BCL2 (0.55) KMT2AKDM4ELMNAMAPTMAPK1
SCHEMBL3521617 0.77 ALDH1A1 (0.51) KMT2ACASRKDM4ELMNAMAPT
SCHEMBL4782916 0.76 CCR9 (0.43) KMT2AGFERMEN1TSHRAPLNR
SCHEMBL4151611 0.76 CASR (0.70) KMT2AGFERCASRKDM4ELMNA
SCHEMBL4784822 0.74 MEN1 (0.45) KMT2AKDM4EMAPTMAPK1MEN1
SCHEMBL4739127 0.72 KMT2A (0.44) KMT2ACASRMEN1TP53
SCHEMBL4985650 0.72 EGLN3 (0.57) KMT2AGFERCPB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2008089051-A1 N-SUBSTITUTED GLYCINE DERIVATIVES: PROLYL HYDROXYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2008-07-24 WO disclosed
US-20080171756-A1 N-Substituted Glycine Derivatives: Prolyl Hydroxylase Inhibitors SMITHKLINE BEECHAM CORPORATION 2008-07-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080171756-A1 N-Substituted Glycine Derivatives: Prolyl Hydroxylase Inhibitors HIF1AN, EGLN2, EGLN3 KMT2A 734/4885GFER 1151/4885CPB1 1469/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.